Critics of gender-affirming care for minors made their case at a day-long workshop before a Federal Trade Commission (FTC) that, under the Trump administration, has warmed to their views.

Companies that can't back up claims that their products are made in the U.S. could face hefty penalties from the Federal Trade Commission.

The FTC has an "unequivocal basis" to investigate the transgender medicine industry, Commissioner Mark Meador says.

DOJ and FTC officials are teaming up to prosecute hospitals, doctors, and drugmakers for performing sex-reassignment procedures on minors.

Commission Chair Andrew Ferguson opened the workshop, titled "The Dangers of 'Gender-Affirming Care' for Minors," and in his remarks said that the agency will issue a request for information in the near future on gender-affirming care, emphasizing that the workshop was "not about politics."

Doctors who pitched medical treatments to minors with gender dysphoria may have deceived them, according to the Federal Trade Commission.

Refusing to investigate practices of so-called gender affirming care for minors, just because one political party opposes scrutiny, is the definition of politicization, Andrew Ferguson tells workshop with detransitioners,